In CRC, intrinsic epidermal growth factor receptor (EGFR) activation circumvents BRAF inhibition, necessitating the concurrent use of EGFR inhibitors, whose treatment strategy led to the approval of encorafenib plus cetuximab for <i>BRAF</i> <sup>V600E</sup> CRC. This evidence concerns the gene BRAF and colorectal carcinoma.